An analysis of prescriptions for coronary heart disease with comorbid conditions in health care institutions of Ukraine
DOI:
https://doi.org/10.14739/2409-2932.2025.1.320493Keywords:
pharmaceutical care, coronary heart disease, type 2 diabetes mellitus, chronic kidney disease, treatment adherence, access to medicinesAbstract
Coronary heart disease (CHD) remains the leading cause of mortality among non-communicable diseases in Ukraine and is often accompanied by various comorbid conditions. Providing pharmaceutical care to patients with CHD and comorbid conditions requires a comprehensive approach that includes ensuring access to medications, supervising rational pharmacotherapy in accordance with domestic and international clinical guidelines, monitoring trends in medication consumption, optimizing the supply of medicines, and developing standards for pharmaceutical care during martial law and the post-war period.
Aim. The objective was to analyze the frequency of medication use by physicians of various specialties for patients with CHD accompanied by type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This was done to identify trends in medication consumption and to optimize the provision of essential medicines in the context of improving the population’s access to medicines during martial law.
Materials and methods. The study was based on an anonymous online survey of 788 physicians from 22 regions of Ukraine, conducted using Google Forms between June and September 2024. The survey was facilitated by the Department of Cardiology at the Shupyk National Healthcare University of Ukraine. The study employed statistical analysis, comparison, generalization, and retrospective methods, alongside clinical-epidemiological approaches, content analysis, and ABC-, VEN-, ATC/DDD-, and frequency analyses.
Results. The pharmaceutical component of CHD management was evaluated based on the frequency of drug prescriptions for pharmacotherapy of CHD with comorbid conditions, following the clinical protocol “Stable Coronary Heart Disease” and clinical guidelines from ESC, AHA, ADA, and KDIGO. Comprehensive ABC-, VEN-, ATC/DDD-, and frequency analyses were conducted to assess prescribing patterns and to optimize the supply of medications to pharmacies and healthcare institutions.
Conclusions. It was found that only 23.65 % of prescribed medications for the pharmacotherapy of CHD with comorbid conditions are covered under the “Affordable Medicines” reimbursement program. This limited coverage negatively impacts treatment adherence, restricts patient access to necessary medications, and hampers the achievement of optimal clinical outcomes. It is recommended to revise and expand the list of reimbursable medications for CHD with comorbid conditions in alignment with current legislation and clinical needs.
References
Navarese EP, Grzelakowska K, Mangini F, Kubica J, Banach M, Benn M, et al. The spoils of war and the long-term spoiling of health conditions of entire nations. Atherosclerosis. 2022;352:76-9. doi: https://doi.org/10.1016/j.atherosclerosis.2022.05.012
The National Health Service of Ukraine. Statystyka stvorennia medychnykh vysnovkiv pro tymchasovu nepratsezdatnist [Statistics of medical conclusions for temporary disability] [Internet]; 2025 [cited 2025 Jan 1]. Available from: https://edata.e-health.gov.ua/e-data/dashboard/mvtn-stats
Bilousova NA, Mykhalchuk VM. Analytical review of the inf l uence of socio-economic factors on the state of pharmaceutical care for patients with cardiovascular diseases. Pol Merkur Lekarski. 2024;52(3):347-55. doi: https://doi.org/10.36740/Merkur202403112
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. doi: https://doi.org/10.1093/eurheartj/ehad192. Erratum in: Eur Heart J. 2023;44(48):5060. doi: https://doi.org/10.1093/eurheartj/ehad774. Erratum in: Eur Heart J. 2024;45(7):518. doi: https://doi.org/10.1093/eurheartj/ehad857
Ministry of Health of Ukraine. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy “Stabilna ishemichna khvoroba sertsia” [Unified clinical protocol for primary, secondary (specialized) and tertiary (highly specialized) medical care “Stable ischemic heart disease”]. Order dated 2021 [Internet]. 2021 Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2021/12/2021_2857_ykpmd_stabihs.pdf
Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022;145(9):e722-e759. doi: https://doi.org/10.1161/CIR.0000000000001040
American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144-S174. doi: https://doi.org/10.2337/dc22-S010. Erratum in: Diabetes Care. 2022;45(5):1296. doi: https://doi.org/10.2337/dc22-er05. Erratum in: Diabetes Care. 2022;45(9):2178-81. doi: https://doi.org/10.2337/dc22-ad08
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi: https://doi.org/10.1016/j.kint.2023.10.018
Nalezhna aptechna praktyka: Standarty yakosti aptechnykh posluh (Spilna nastanova MFF/VOOZ z NAP) [Good pharmacy practice: Standards of quality of pharmacy services (Joint guideline of the IFF/WHO with the National Health Service)]. 2011 Jan 1 [cited 2025 Jan 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/897_009#Text
Bilousova N. [Justification for expanding the pharmacist’s role in the prevention of coronary heart disease at secondary and tertiary levels of medical care]. Modern Medicine, Pharmacy and Psychological Health. 2024;(3):41-50. Ukrainian. doi: https://doi.org/10.32689/2663-0672-2024-3-7
Bilousova NA. [Primary prevention of a coronary heart disease within the structure of pharmaceutical care provision: functional role fulfillment of the pharmacist]. Pharmaceutical Review. 2024;(3):42-52. Ukrainian. doi: https://doi.org/10.11603/2312-0967.2024.3.14862
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi: https://doi.org/10.1097/HJH.0000000000003480. Erratum in: J Hypertens. 2024;42(1):194. doi: https://doi.org/10.1097/HJH.0000000000003621
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: https://doi.org/10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021;42(48):4901. doi: https://doi.org/10.1093/eurheartj/ehab670
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi: https://doi.org/10.1161/CIR.0000000000001193. Erratum in: Circulation. 2024;149(1):e167. doi: https://doi.org/10.1161/CIR.0000000000001207. Erratum in: Circulation. 2024;149(9):e936. doi: https://doi.org/10.1161/CIR.0000000000001218. Erratum in: Circulation. 2024;149(24):e1413. doi: https://doi.org/10.1161/CIR.0000000000001263
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi: https://doi.org/10.1161/CIR.0000000000001168. Erratum in: Circulation. 2023;148(13):e148. doi: https://doi.org/10.1161/CIR.0000000000001183. Erratum in: Circulation. 2023;148(23):e186. doi: https://doi.org/10.1161/CIR.0000000000001195
Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Brouse S, Butler J, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444-88. doi: https://doi.org/10.1016/j.jacc.2023.12.024
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. doi: https://doi.org/10.1093/eurheartj/ehad191. Erratum in: Eur Heart J. 2024;45(13):1145. doi: https://doi.org/10.1093/eurheartj/ehad870
Kirsanov D. Aptechnyi prodazh za pidsumkamy I pivrichchia 2024 r. [Pharmacy sales for pidsumkamy and pivrichchia 2024]. Apteka online [Internet]. 2024;(28/29). Ukrainian. Available from: https://www.apteka.ua/article/698730
Ministry of Health of Ukraine. Pro zatverdzhennia shistnadtsiatoho vypusku Derzhavnoho formuliara likarskykh zasobiv ta zabezpechennia yoho dostupnosti [On approval of the sixteenth edition of the State Formulary of Medicinal Products and ensuring its accessibility]. Order dated 2024 Mar 12 No. 418 [Internet]. 2024 [cited 2025 Jan 1]. Ukrainian. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukraini-vid-10052024--809-pro-zatverdzhennja-pasporta-bjudzhetnoi-programi-na-2024-rik
Ministry of Health of Ukraine. Infektsii sechovyvidnykh shliakhiv [Infections of the urethral sphincters]. Order dated 2017 May 22 No. 00232 [Internet]. Ukrainian. Available from: https://guidelines.moz.gov.ua/documents/3120
Hernández-Hernández D, Ortega-González Y, Padilla-Fernández B, Gutiérrez-Hernández PR, Castro-Díaz DM. Management of Acute Cystitis in the Era of COVID-19. Curr Bladder Dysfunct Rep. 2023;18(1):10-5. doi: https://doi.org/10.1007/s11884-022-00677-0
Dicu-Andreescu I, Penescu MN, Căpușă C, Verzan C. Chronic Kidney Disease, Urinary Tract Infections and Antibiotic Nephrotoxicity: Are There Any Relationships? Medicina (Kaunas). 2022;59(1):49. doi: https://doi.org/10.3390/medicina59010049
Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19-62. doi: https://doi.org/10.1038/kisup.2012.64
Facts about chronic kidney disease [Internet]. National Kidney Foundation. [cited 2025 Jan 1]. Available from: https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd
WebCardio.org. Sertsevo-sudynno-nyrkovo-metabolichnyi syndrom [Cardiovascular-renal-metabolic syndrome] [Internet]. 2023 Oct 11 [cited 2025 Jan 1]. Ukrainian. Available from: https://www.webcardio.org/sertsevo-sudynno-nyrkovo-metabolichnyj-syndrom.aspx
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35. doi: https://doi.org/10.1161/CIR.0000000000001184. Erratum in: Circulation. 2024;149(13):e1023. doi: https://doi.org/10.1161/CIR.0000000000001241
Compendium. Firialta [Internet]; [cited 2025 Jan 1]. Available from: https://compendium.com.ua/dec/572863/
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127. doi: https://doi.org/10.1016/j.kint.2022.06.008
Kabinet of Ministers of Ukraine. Deiaki pytannia derzhavnoho rehuliuvannia tsin na likarski zasoby i vyroby medychnoho pryznachennia [Some issues of state regulation of prices for medical supplies and medical products]. Order dated 2009 Mar 25 No. 333 [Internet]. 2024 [cited 2025 Jan 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/333-2009-п#Text
EEML – electronic essential medicines list [Internet]. Essentialmeds.org. [cited 2025 Jan 22]. Available from: https://list.essentialmeds.org
Ministry of Health of Ukraine. Perelik likarskykh zasobiv, yaki pidliahaiut reimbursatsii za prohramoiu derzhavnykh harantii medychnoho obsluhovuvannia naselennia, stanom na 23 hrudnia 2024 roku [List of medicines subject to reimbursement under the program of state guarantees of medical care for the population, as of December 23, 2024]. Order dated 2024 Dec 25 [Internet]. 2024 [cited 2025 Jan 1]. Ukrainian. Available from: https://moz.gov.ua/storage/uploads/94007481-c844-4e8e-9946-e36f90ac8240/dn_2148_25122024_dod.pdf
De Smedt D, Kotseva K, De Bacquer D, Wood D, De Backer G, Dallongeville J, et al. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. Eur Heart J. 2012;33(22):2865-72. doi: https://doi.org/10.1093/eurheartj/ehs210
De Smedt D, Annemans L, De Backer G, Kotseva K, Rydèn L, Wood D, et al. Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. Int J Cardiol. 2018;272:20-5. doi: https://doi.org/10.1016/j.ijcard.2018.06.104
Ministry of Health of Ukraine. Pro zatverdzhennia Poriadku vkliuchennia (vykliuchennia) likarskykh zasobiv do (z) Natsionalnoho pereliku osnovnykh likarskykh zasobiv ta/abo do (z) nomenklatur likarskykh zasobiv, shcho zakupovuiutsia za koshty derzhavnoho biudzhetu dlia vykonannia prohram ta zdiisnennia tsentralizovanykh zakhodiv z okhorony zdorovia, iz zastosuvanniam derzhavnoi otsinky medychnykh tekhnolohii [On approval of the Procedure for inclusion (exclusion) of medical products in (from) the National List of Basic Medical Products and/or in (from) the Nomenclature of Medical Products, which are purchased at the expense of the state budget for the implementation of programs and for the implementation of centralized health care systems, using state estimates of medical technologies]. Order dated 2022 Jan 4 [Internet]. 2024 Jul 5 [cited 2025 Jan 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/z0095-22#Text
Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636-48. doi: https://doi.org/10.1177/2047487315569401
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021;28(4):370-9. doi: https://doi.org/10.1177/2047487320908698
Ministry of Health of Ukraine. Pro zatverdzhennia protokoliv farmatsevta [On approval of pharmacist protocols]. Order dated 2022 Jan 5 [Internet]. 2022 [cited 2025 Jan 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/rada/show/v0007282-22#Text
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
